Aleth Gaillard
About Aleth Gaillard
Aleth Gaillard is a scientist at Tessera Therapeutics in Cambridge, Massachusetts, where she has worked since 2020. She specializes in single-cell RNA-sequencing and synthetic biology, holding a PhD in Chemistry from the Massachusetts Institute of Technology.
Work at Tessera Therapeutics
Aleth Gaillard has been employed as a Scientist at Tessera Therapeutics since 2020. Located in Cambridge, Massachusetts, Gaillard contributes to the company's research initiatives, focusing on innovative approaches in the field of synthetic biology. The role involves applying advanced techniques such as single-cell RNA-sequencing to explore complex biological systems, particularly in relation to the tumor micro-environment.
Education and Expertise
Gaillard holds a Doctor of Philosophy (PhD) in Chemistry from the Massachusetts Institute of Technology, where studies were conducted from 2014 to 2020. Prior to this, Gaillard earned a Master's degree in Biochemistry and Molecular Biology from Université Pierre et Marie Curie (Paris VI) in 2014. Additionally, a Master's degree in Chemistry was obtained from Ecole normale supérieure de Cachan in 2014. Gaillard's academic background provides a strong foundation in next-generation sequencing (NGS) techniques and synthetic biology.
Background
Before joining Tessera Therapeutics, Aleth Gaillard spent six years at the Massachusetts Institute of Technology, initially as an intern during a gap year from 2012 to 2013 and later as a Graduate Student from 2014 to 2020. Gaillard also gained experience through internships at the University of Florida in 2012 and Institut Curie in 2011. This diverse background in prestigious institutions has contributed to Gaillard's expertise in biological research and synthetic biology.
Research Contributions
During PhD research, Aleth Gaillard developed tools for single-cell sequencing utilizing synthetic biology techniques, including Cas9 and recombinases. Gaillard's research interests focus on organism engineering and the application of NGS and screening technologies to address specific biological questions. This work aims to enhance understanding of biological systems and contribute to advancements in the field of synthetic biology.